Alta Prevalência de Dislipidemias em Crianças e Adolescentes: Oportunidade para Prevenção

Mangili, Leonardo Celeste

doi:10.36660/abc.20190761

Cited by 5 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As dislipidemias se encontram difundidas amplamente na população brasileira, como revelam os dados da Pesquisa Nacional de Saúde (PNS) de 2013, que apresentava uma prevalência de dislipidemia autorreferida de 12,5% na população acima de 18 anos e de até 24,8% de prevalência de acordo com dados da pesquisa de Vigilância de Fatores de Risco e Proteção para Doenças Crônicas por Inquérito Telefônico (VIGITEL) do ano de 2016 (LOTUFO et al, 2017;MANGILI, 2020). Além disso, dados de estudos observacionais revelaram ao avaliar indivíduos obesos uma prevalência que chega até 75%, evidenciando o papel da avaliação das dislipidemias como um indicador de saúde pública.…”

Section: Introductionunclassified

Quais são as novas evidências para o manejo das dislipidemias? Uma revisão integrativa

Santana¹,

Freire²,

Netto³

et al. 2023

Braz. J. Hea. Rev.

View full text Add to dashboard Cite

As dislipidemias se encontram difundidas amplamente na população brasileira, com uma prevalência de 24,8% e de até 75% em indivíduos obesos. O presente estudo de revisão buscou avaliar novos avanços para a abordagem terapêutica das dislipidemias, documentados por meio de estudos clínicos e randomizados. Trata-se de uma pesquisa de revisão integrativa realizada por meio da base de dados PubMed, que levou em consideração os seguintes critérios de inclusão: ensaios clínicos e testes controlados e randomizados; artigos publicados no último ano; que possuíam texto completo disponível e que abordassem acerca do manejo das dislipidemias. Ficou constatado que a terapia conjunta de pitavastatina e ezetimiba reduz, de forma significativa, os níveis de LDL-colesterol quando comparado com a monoterapia com pitavastatina, sem aumentar o número de eventos adversos gerais. Outra medida eficaz, ao se combinar a ezetimiba com a atorvastatina, houve uma maior eficácia na redução do nível de LDL-colesterol quando comparado com a monoterapia com atorvastatina. Além disso, observa-se o impacto positivo da suplementação de produto rico em polifenóis para a redução de lipídios no sangue, possibilitando um efeito protetor contra a aterosclerose, da mesma forma que a suplementação oral combinada de hidroxitirosol e punicalagina, a qual reduziu, de forma significativa, os níveis plasmáticos de LDL-colesterol e de triglicerídeos. Por fim, o uso do recaticimabe também pode ser aplicado como terapia adjuvante à estatina em indivíduos com hipercolesterolemia, reduzindo o nível de LDL-colesterol e tornando-se uma nova opção de tratamento segura e eficaz para o manejo de tal dislipidemia.

show abstract

Section: Introductionunclassified

Quais são as novas evidências para o manejo das dislipidemias? Uma revisão integrativa

Santana¹,

Freire²,

Netto³

et al. 2023

Braz. J. Hea. Rev.

View full text Add to dashboard Cite

show abstract

“…Atherosclerotic cardiovascular disease remains the leading cause of death and a major cause of morbidity [ 1 , 2 ]. Although clinical outcomes (e.g., death, stroke, myocardial infarction) rarely occur in youth, mounting evidence suggests that atherosclerotic lesions can begin in childhood [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Treatment of Dyslipidaemia in Children

Fiorentino

Chiarelli

2021

Biomedicines

View full text Add to dashboard Cite

Childhood dyslipidaemia is one of the main traditional cardiovascular risk factors that initiate and exacerbate the atherosclerotic process. Healthcare providers may play a key role in the management of children with lipid abnormalities; however, they have to properly evaluate the normal lipid values and know the available treatment options in children and adolescents. Current guidelines recommend healthy behaviours as the first-line treatment for childhood dyslipidaemia. The therapeutic lifestyle changes should focus on dietary modifications, daily physical activity, reduction in body weight and tobacco smoking cessation. Parents play a key role in promoting their children’s healthy habits. In children with more severe forms of lipid abnormalities and in those who do not benefit from healthy behaviours, pharmacological therapy should be considered. Safe and effective medications are already available for children and adolescents. Statins represent the first-line pharmacological option, while ezetimibe and bile acid sequestrants are usually used as second-line drugs. Despite their limited use in children, other lipid-lowering agents (already approved for adults) are currently available or under study for certain categories of paediatric patients (e.g., familial hypercholesterolemia). Further studies are needed to evaluate the long-term efficacy, safety and tolerability of novel lipid-lowering drugs, especially in children.

show abstract

Quantifying the burden of lipid anomalies among adolescents in India

Chauhan

Singh

2022

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background The present study’s aim is to quantify the burden of lipid abnormalities (excessive non-high-density lipoprotein (non-HDL) cholesterol and low-density lipoprotein (LDL) cholesterol) among Indian adolescents. Which has emerged as a significant covariate of coronary heart disease (CHD). Methods The present study aims to unearth the prevalence of any lipid anomalies, their level, and types of lipid profiles among adolescents in India using the Comprehensive National Nutrition Survey 2016–18 i.e., cross-sectional data. Descriptive and bivariate statistical analyses have been used to check the associations and significant differences between groups of individuals suffering from any type of lipid abnormalities. Results A total of 35,830 adolescents aged between 10 and 19 years (mean age:14.36 yrs.; SD = 2.81 for males and 14.39 yrs.; SD = 2.78 for females) were included. Roughly 77 percent of the adolescents are suffering from any lipid anomalies. Their mean lipid levels are 140.6 (SD = 32.9), 84.1 (SD = 24.8), 47.3 (SD = 10.7), and 95.3 (SD = 50.0) for total cholesterol, LDL, HDL, and triglycerides, respectively. A higher proportion of adolescents suffered from lipid anomalies among those who were overweight or obese (89%, 95% CI 85, 92) and pre-diabetics (81%, 95% CI 78, 83) compared to each of their counterparts. Furthermore, a considerable proportion of samples with vitamin A (70%, 95% CI 68, 73), D (81%, 95% CI 79, 82), and B12 deficits (73%,95% CI 72, 75), as well as zinc (77%, 95% CI 76, 77), folate (76%, 95% CI 74, 77), and iron deficits (75%,95% CI 73, 77), were suffering from any lipid anomalies. Of individuals who consume an unhealthy diet, 77% (95% CI 76, 78) of them were suffering from any lipid anomalies than others. Conclusions The study contends that preventing the increasing burden of lipid abnormalities among Indian adolescents is essential. Vitamin and mineral deficiencies and unhealthy dietary habits are significantly associated with high LDL and non-HDL levels. In the longer run, this might cause the early onset of hypertension, diabetes, and CHDs. Hence, appropriate interventions are needed to curtail these early onsets by primarily focusing on adolescents.

show abstract

Alta Prevalência de Dislipidemias em Crianças e Adolescentes: Oportunidade para Prevenção

Cited by 5 publications

References 9 publications

Quais são as novas evidências para o manejo das dislipidemias? Uma revisão integrativa

Quais são as novas evidências para o manejo das dislipidemias? Uma revisão integrativa

Treatment of Dyslipidaemia in Children

Quantifying the burden of lipid anomalies among adolescents in India

Contact Info

Product

Resources

About